Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-drug interaction study of nemolizumab with CYP substrates in moderate-to-severe atopic dermatitis
2020-000229-24Phase 2Completed
- Sponsor
- Galderma
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Primary endpoint: Effect of nemolizumab on CYP substrate pharmacokinetics. Started Nov 2020; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-000229-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000229-24.